keyword
MENU ▼
Read by QxMD icon Read
search

comparative efficacy of ppis

keyword
https://www.readbyqxmd.com/read/28025156/a-modern-magnetic-implant-for-gastroesophageal-reflux-disease-gerd
#1
Robert A Ganz
A magnetic implant for the treatment of GERD was FDA-approved in 2012 and has been extensively evaluated. The device is a ring of magnets, that are placed around the gastroesophageal junction, augmenting the native lower esophageal sphincter and preventing reflux yet preserving LES physiologic function and allowing belching and vomiting. Magnetic force is advantageous, being permanent and precise, and forces between magnets decrease with esophageal displacement. Multiple patient cohorts have been studied using the magnetic device, and trials establish consistent, long-term improvement in pH data, GERD symptom scores and PPI use...
December 23, 2016: Clinical Gastroenterology and Hepatology
https://www.readbyqxmd.com/read/27992223/revealing-the-mechanistic-pathway-of-acid-activation-of-proton-pump-inhibitors-to-inhibit-the-gastric-proton-pump-a-dft-study
#2
Kalyanashis Jana, Tusar Bandyopadhyay, Bishwajit Ganguly
Acid-related gastric diseases are associated with disorder of digestive tract acidification due to the acid secretion by gastric proton pump, H(+),K(+)-ATPase. Omeprazole is one of the persuasive irreversible inhibitor of the proton pump H(+),K(+)-ATPase. However, the reports on the mechanistic pathway of irreversible proton pump inhibitors (PPIs) on the acid activation and formation of disulfide complex are scarce in the literature. We have examined the acid activation PPIs, i.e., timoprazole, S-omeprazole and R-omeprazole using M062X/6-31++G(d,p) in aqueous phase with SMD solvation model...
December 29, 2016: Journal of Physical Chemistry. B
https://www.readbyqxmd.com/read/27981489/influence-of-low-dose-proton-pump-inhibitors-administered-concomitantly-or-separately-on-the-anti-platelet-function-of-clopidogrel
#3
Takahisa Furuta, Mitsushige Sugimoto, Chise Kodaira, Masafumi Nishino, Mihoko Yamade, Takahiro Uotani, Shu Sahara, Hitomi Ichikawa, Takuma Kagami, Moriya Iwaizumi, Yasushi Hamaya, Satoshi Osawa, Ken Sugimoto, Kazuo Umemura
Proton pump inhibitors (PPIs) at low doses can effectively prevent gastrointestinal bleeding due to aspirin and are widely used in Japan for gastroprotection in patients taking anti-platelet agents. We examined the influence of different PPIs at low doses administered concomitantly or separately on anti-platelet functions of clopidogrel. In 41 healthy Japanese volunteers with different CYP2C19 genotypes who took clopidogrel 75 mg in the morning alone, or with omeprazole 10 mg, esomeprazole 10 mg, lansoprazole 15 mg, or rabeprazole 10 mg, either concomitantly in the morning or separately in the evening, we measured the inhibition of platelet aggregation (IPA, %) using VerifyNow P2Y12 assay at 4 h after the last clopidogrel dose on Day 7 of each regimen...
December 15, 2016: Journal of Thrombosis and Thrombolysis
https://www.readbyqxmd.com/read/27937054/efficacy-of-aspirin-325-mg-omeprazole-40-mg-in-treating-coronary-artery-disease
#4
Tushar Sharma, Kevin Bliden, Rahul Chaudhary, Udaya Tantry, Paul A Gurbel
Aspirin is indicated for primary and secondary prevention of cardiovascular diseases (CVD) by major guidelines. However, its use may be associated with gastrointestinal (GI) toxicities, including, but not limited to, GI bleeding. This may lead to increased morbidity and mortality, as well as diminished compliance, which again leads to increased risk of major cardiovascular events. Modified formulations of aspirin often have comparable risks of GI toxicity despite their dose or formulation and have had limited success to prevent GI toxicities...
January 2017: Expert Opinion on Pharmacotherapy
https://www.readbyqxmd.com/read/27907909/egfr-kinase-inhibitors-and-gastric-acid-suppressants-in-egfr-mutant-nsclc-a-retrospective-database-analysis-of-potential-drug-interaction
#5
Nesaretnam Barr Kumarakulasinghe, Nicholas Syn, Yu Yang Soon, Atasha Asmat, Huili Zheng, En Yun Loy, Brendan Pang, Ross Andrew Soo
BACKGROUND: Erlotinib and gefitinib are weak base drugs whose absorption and clinical efficacy may be impaired by concomitant gastric acid suppressive (AS) therapy, yet proton pump inhibitors (PPIs) and histamine-2 receptor antagonists (H2As) are widely indicated in non-small cell lung cancer (NSCLC) patients for the prevention and treatment of erlotinib-induced gastrointestinal injury and corticosteroid-associated gastric irritation. We assessed the clinical relevance of this potential drug-drug interaction (DDI) in a retrospective cohort of EGFR-mutant NSCLC patients...
November 19, 2016: Oncotarget
https://www.readbyqxmd.com/read/27855401/systematic-review-and-net-work-meta-analysis-of-upper-gastrointestinal-hemorrhage-interventions
#6
Mengyuan Jiang, Pan Chen, Qiang Gao
BACKGROUND/AIMS: Upper gastrointestinal hemorrhage (UGH) is a serious medical condition which affects a large number of individuals. Endoscopic therapy accompanied by medication is a standard approach that is used to improve the prognosis of UGH patients and a few medications have been developed including proton pump inhibitors (PPIs), histamine H2 receptor antagonist (H2RA), somatostatin analogues and tranexamic acid. This study is set to compare the efficacy and safety of various medical interventions that are used to manage upper gastrointestinal bleeding...
2016: Cellular Physiology and Biochemistry
https://www.readbyqxmd.com/read/27806639/analysis-of-the-cost-effectiveness-of-using-vonoprazan-amoxicillin-clarithromycin-triple-therapy-for-first-line-helicobacter-pylori-eradication
#7
Yusaku Kajihara, Tadashi Shimoyama, Ichiro Mizuki
BACKGROUND: Vonoprazan (VPZ)-based triple therapy has been reported to have greater efficacy than a proton pump inhibitor (PPI)-based triple therapy for Helicobacter pylori (H. pylori) eradication. However, because VPZ is more expensive than PPIs such as rabeprazole (RPZ), economic evaluation is essential. METHODS: We performed a retrospective study on 209 patients who underwent first-line eradication of H. pylori infection in Fuyoukai Murakami Hospital from 1 March 2015 to 31 March 2016...
February 2017: Scandinavian Journal of Gastroenterology
https://www.readbyqxmd.com/read/27782887/comparison-of-the-effects-of-esomeprazole-40-mg-rabeprazole-20-mg-lansoprazole-30-mg-and-pantoprazole-40-mg-on-intragastr%C3%A4-c-ph-in-extensive-metabolizer-patients-with-gastroesophageal-reflux-disease
#8
Altay Çelebi, Dinçer Aydın, Orhan Kocaman, Buğra Tolga Konduk, Ömer Şentürk, Sadetin Hülagü
BACKGROUND/AIMS: Studies on the therapeutic efficacy of proton pump inhibitors (PPIs) in patients with gastroesophageal reflux disease (GERD) have been recently published. In most of these studies, comparison of only two PPIs have been made. There are few studies on the comparison of four or more PPIs. We aimed to compare the acid inhibitory effects of esomeprazole 40 mg, rabeprazole 20 mg, lansoprazole 30 mg, and pantoprazole 40 mg on days 1 and 5 of treatment in patients with GERD, who were extensive metabolizers in regard to the CYP2C19 genotype...
September 2016: Turkish Journal of Gastroenterology: the Official Journal of Turkish Society of Gastroenterology
https://www.readbyqxmd.com/read/27737436/association-of-proton-pump-inhibitors-and-capecitabine-efficacy-in-advanced-gastroesophageal-cancer-secondary-analysis-of-the-trio-013-logic-randomized-clinical-trial
#9
Michael P Chu, J Randolph Hecht, Dennis Slamon, Zev A Wainberg, Yung-Jue Bang, Paulo M Hoff, Alberto Sobrero, Shukui Qin, Karen Afenjar, Vincent Houe, Karen King, Sheryl Koski, Karen Mulder, Julie Price Hiller, Andrew Scarfe, Jennifer Spratlin, Yingjie J Huang, Saba Khan-Wasti, Neil Chua, Michael B Sawyer
Importance: Capecitabine is an oral cytotoxic chemotherapeutic commonly used across cancer subtypes. As with other oral medications though, it may suffer from drug interactions that could impair its absorption. Objective: To determine if gastric acid suppressants such as proton pump inhibitors (PPIs) may impair capecitabine efficacy. Design, Setting, and Participants: This secondary analysis of TRIO-013, a phase III randomized trial, compares capecitabine and oxaliplatin (CapeOx) with or without lapatinib in 545 patients with ERBB2/HER2-positive metastatic gastroesophageal cancer (GEC); patients were randomized 1:1 between CapeOx with or without lapatinib...
October 13, 2016: JAMA Oncology
https://www.readbyqxmd.com/read/27637911/concomitant-use-of-proton-pump-inhibitors-and-clopidogrel-increases-the-risk-of-adverse-outcomes-in-patients-with-ischemic-stroke-carrying-reduced-function-cyp2c19-2
#10
Xingyang Yi, Zhao Han, Qiang Zhou, Wen Cheng, Jing Lin, Chun Wang
OBJECTIVE: Conflicting data exist as to whether proton-pump inhibitors (PPIs) diminish the efficacy of clopidogrel. The aim of this study was to investigate the association between cytochrome P450 (CYP) genetic variants and clinical adverse outcomes of concomitant use of PPIs and clopidogrel by patients. METHODS: We consecutively enrolled 523 patients with ischemic stroke receiving clopidogrel. Platelet aggregation was measured before and after 7 to 10 days of clopidogrel treatment...
September 16, 2016: Clinical and Applied Thrombosis/hemostasis
https://www.readbyqxmd.com/read/27605258/a-randomized-double-blind-active-controlled-multi-center-study-of-ilaprazole-in-the-treatment-of-reflux-esophagitis
#11
RANDOMIZED CONTROLLED TRIAL
Yan Xue, Xianghong Qin, Liya Zhou, Sanren Lin, Ling Wang, Haitang Hu, Jielai Xia
BACKGROUND AND OBJECTIVE: Proton pump inhibitors (PPIs) are the main drugs for the treatment of reflux esophagitis. Previous studies have indicated ilaprazole to be safer and more effective in treating duodenal ulcers as compared with omeprazole. Being a novel PPI, ilaprazole may be used in the treatment of reflux esophagitis. The purpose of this study was to evaluate the safety and efficacy of ilaprazole tablets in the treatment of reflux esophagitis. METHODS: This study used a randomized, double-blind, multi-center, active-comparison design...
December 2016: Clinical Drug Investigation
https://www.readbyqxmd.com/read/27598861/ilaprazole-for-the-treatment-of-gastro-esophageal-reflux
#12
Edoardo Savarino, Andrea Ottonello, Irene Martinucci, Pietro Dulbecco, Vincenzo Savarino
INTRODUCTION: Despite the undoubted benefit of proton pump inhibitors (PPIs), they have several shortcomings, such as a slow onset of action and a remarkable inter-individual variability, that limit the complete success of these drugs. Recently, a new PPI, ilaprazole, has been developed and used in GERD patients. AREAS COVERED: The present review provides an update on the following points: current knowledge of GERD mechanisms; limitations of actual therapies; pharmacokinetic profile and metabolism of ilaprazole; initial studies on the therapeutic efficacy of ilaprazole in GERD...
October 2016: Expert Opinion on Pharmacotherapy
https://www.readbyqxmd.com/read/27581096/the-efficacy-and-safety-of-proton-pump-inhibitors-in-treating-patients-with-non-erosive-reflux-disease-a-network-meta-analysis
#13
Lingxiao Chen, Yujie Chen, Bo Li
Proton-pump inhibitors (PPIs) have been proved as safe and effective ways to treat patients with non-erosive reflux disease (NERD). However, less is known about the comparisons among different PPIs and their best dosage. We aimed to synthesize the available evidence through network meta-analysis to investigate the efficacy and safety of different PPIs in treating patients with NERD. Fifteen studies with 6309 patients were included in the meta-analyses. For the rate of symptomatic relief, compared with control groups, all interventions except rabeprazole 5 mg significantly increased rate of symptomatic relief...
September 1, 2016: Scientific Reports
https://www.readbyqxmd.com/read/27580358/dexlansoprazole-delayed-release-orally-disintegrating-tablets-for-the-treatment-of-heartburn-associated-with-non-erosive-gastroesophageal-reflux-disease-and-the-maintenance-of-erosive-esophagitis
#14
Edward C Oldfield Iv, Parth J Parekh, David A Johnson
INTRODUCTION: Gastroesophageal reflux disease (GERD) is a common clinical condition afflicting millions of patients, whose prevalence continues to rise owing to the aging population and increasing burden of comorbid conditions, such as obesity. Currently, the mainstay of therapy for GERD is treatment with proton pump inhibitors (PPIs). Despite their overall efficacy, safety, and tolerability, there are still a considerable number of patients who fail treatment and have refractory symptoms to PPI therapy...
August 31, 2016: Expert Review of Gastroenterology & Hepatology
https://www.readbyqxmd.com/read/27534444/vonoprazan-versus-conventional-proton-pump-inhibitor-based-triple-therapy-as-first-line-treatment-against-helicobacter-pylori-a-multicenter-retrospective-study-in-clinical-practice
#15
Satoki Shichijo, Yoshihiro Hirata, Ryota Niikura, Yoku Hayakawa, Atsuo Yamada, Satoshi Mochizuki, Keigo Matsuo, Yoshihiro Isomura, Motoko Seto, Nobumi Suzuki, Hirobumi Suzuki, Shinzo Yamamoto, Takafumi Sugimoto, Tomoya Omae, Makoto Okamoto, Hirotsugu Watabe, Goichi Togo, Noriyuki Takano, Keisuke Fukui, Yuri Ito, Kazuhiko Koike
OBJECTIVE: Vonoprazan is a potassium-competitive acid blocker, a new type of acid-suppressing drug, and has recently become available for peptic ulcers, gastroesophageal reflux disease, and Helicobacter pylori (H. pylori) eradication. Its efficacy for H. pylori eradication has been reported. However, the evidence for its efficacy and feasibility remains limited. We aimed to compare the feasibility, effectiveness and safety of vonoprazan-based triple therapy with conventional proton pump inhibitor (PPI)-based triple therapy in multicenter clinical practice...
October 2016: Journal of Digestive Diseases
https://www.readbyqxmd.com/read/27514776/potassium-competitive-acid-blockers-advanced-therapeutic-option-for-acid-related-diseases
#16
Nobuhiro Inatomi, Jun Matsukawa, Yuuichi Sakurai, Kazuyoshi Otake
Acid-related diseases (ARDs), such as peptic ulcers and gastroesophageal reflux disease, represent a major health-care concern. Some major milestones in our understanding of gastric acid secretion and ARD treatment reached during the last 50years include 1) discovery of histamine H2-receptors and development of H2-receptor antagonists, 2) identification of H(+),K(+)-ATPase as the parietal cell proton pump and development of proton pump inhibitors (PPIs), and 3) identification of Helicobacter pylori (H. pylori) as the major cause of peptic ulcers and development of effective eradication regimens...
December 2016: Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/27495332/efficacy-of-transoral-incisionless-fundoplication-tif-for-the-treatment-of-gerd-a-systematic-review-with-meta-analysis
#17
Xiaoquan Huang, Shiyao Chen, Hetong Zhao, Xiaoqing Zeng, Jingjing Lian, Yujen Tseng, Jie Chen
BACKGROUND: The efficacy of transoral incisionless fundoplication (TIF) performed with the EsophyX device (Redmond, Washington, USA) and its long-term outcomes in gastresophageal reflux disease (GERD) are debated. We, therefore, performed a systematic review with meta-analysis of studies evaluating the role of TIF in GERD. METHODS: A systematic search of EMBASE, SCOPUS, PubMed, and the Cochrane Library Central was performed. All original studies reporting outcomes in GERD patients who underwent TIF were identified...
August 5, 2016: Surgical Endoscopy
https://www.readbyqxmd.com/read/27492962/vonoprazan-is-superior-to-proton-pump-inhibitors-in-healing-artificial-ulcers-of-the-stomach-post-endoscopic-submucosal-dissection-a-propensity-score-matching-analysis
#18
Daisuke Maruoka, Makoto Arai, Shingo Kasamatsu, Hideaki Ishigami, Takashi Taida, Kenichiro Okimoto, Keiko Saito, Tomoaki Matsumura, Tomoo Nakagawa, Tatsuro Katsuno, Osamu Yokosuka
BACKGROUND AND AIM: Proton pump inhibitors (PPI) are effective at healing artificial ulcers after endoscopic submucosal dissection (ESD) for gastric neoplasms; however, the efficacy of vonoprazan is not completely understood. The aim of the present study was to determine the healing effect of vonoprazan on artificial ulcers post-gastric ESD relative to PPI. METHODS: Thirty-five patients who underwent gastric ESD between April and November 2015 were treated with vonoprazan 20 mg/day for 4 weeks and subsequently underwent endoscopy for evaluation of ulcer size (V group)...
August 4, 2016: Digestive Endoscopy: Official Journal of the Japan Gastroenterological Endoscopy Society
https://www.readbyqxmd.com/read/27446535/efficacy-of-alfacalcidol-and-alendronate-on-lumbar-bone-mineral-density-in-osteoporotic-patients-using-proton-pump-inhibitors
#19
Daisuke Asaoka, Akihito Nagahara, Mariko Hojo, Kenshi Matsumoto, Hiroya Ueyama, Kohei Matsumoto, Kentaro Izumi, Tsutomu Takeda, Hiroyuki Komori, Yoichi Akazawa, Yuji Shimada, Taro Osada, Sumio Watanabe
It has been indicated that proton pump inhibitor (PPI) use is associated with a loss of the anti-fracture efficacy of alendronate (AD). However, there are few prospective studies that have investigated the efficacy of AD on lumbar bone mineral density (BMD) in osteoporotic patients who are using PPIs. Thus, the aim of the present study was to investigate the efficacy of alfacalcidol (AC) and AD on lumbar BMD in osteoporotic patients using PPIs. A prospective, randomized, active control study enrolled such osteoporotic patients (age, ≥50 years)...
August 2016: Biomedical Reports
https://www.readbyqxmd.com/read/27433347/a-randomized-crossover-pharmacodynamic-study-of-immediate-release-omeprazole-sodium-bicarbonate-and-delayed-release-lansoprazole-in-healthy-adult-volunteers
#20
Vijayalakshmi S Pratha, Thomas McGraw, William Tobin
Proton pump inhibitors (PPIs) effectively block gastric acid secretion and are the treatment of choice for heartburn. PPIs differ, however, in onset of action and bioavailability. In this single-center, open-label, three-way crossover study, onset of action of immediate-release omeprazole 20 mg/sodium bicarbonate 1100 mg (IR-OME) and delayed-release (DR) lansoprazole 15 mg was evaluated in 63 healthy fasting adults. Subjects were randomized to once daily IR-OME, or DR-lansoprazole, or no treatment for 7 days...
June 2016: Pharmacology Research & Perspectives
keyword
keyword
45167
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"